JP2020536587A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536587A5
JP2020536587A5 JP2020542046A JP2020542046A JP2020536587A5 JP 2020536587 A5 JP2020536587 A5 JP 2020536587A5 JP 2020542046 A JP2020542046 A JP 2020542046A JP 2020542046 A JP2020542046 A JP 2020542046A JP 2020536587 A5 JP2020536587 A5 JP 2020536587A5
Authority
JP
Japan
Prior art keywords
composition according
positions
oligonucleotide
chain
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542046A
Other languages
English (en)
Japanese (ja)
Other versions
JP7308213B2 (ja
JP2020536587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055735 external-priority patent/WO2019075419A1/en
Publication of JP2020536587A publication Critical patent/JP2020536587A/ja
Publication of JP2020536587A5 publication Critical patent/JP2020536587A5/ja
Priority to JP2023109290A priority Critical patent/JP7674420B2/ja
Application granted granted Critical
Publication of JP7308213B2 publication Critical patent/JP7308213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542046A 2017-10-13 2018-10-12 Ldhaの発現を阻害するための方法及び組成物 Active JP7308213B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023109290A JP7674420B2 (ja) 2017-10-13 2023-07-03 Ldhaの発現を阻害するための方法及び組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762572403P 2017-10-13 2017-10-13
US201762572398P 2017-10-13 2017-10-13
US62/572,403 2017-10-13
US62/572,398 2017-10-13
US201862726950P 2018-09-04 2018-09-04
US62/726,950 2018-09-04
PCT/US2018/055735 WO2019075419A1 (en) 2017-10-13 2018-10-12 METHODS AND COMPOSITIONS FOR INHIBITING LDHA EXPRESSION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023109290A Division JP7674420B2 (ja) 2017-10-13 2023-07-03 Ldhaの発現を阻害するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020536587A JP2020536587A (ja) 2020-12-17
JP2020536587A5 true JP2020536587A5 (cg-RX-API-DMAC7.html) 2023-03-01
JP7308213B2 JP7308213B2 (ja) 2023-07-13

Family

ID=66101691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542046A Active JP7308213B2 (ja) 2017-10-13 2018-10-12 Ldhaの発現を阻害するための方法及び組成物
JP2023109290A Active JP7674420B2 (ja) 2017-10-13 2023-07-03 Ldhaの発現を阻害するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023109290A Active JP7674420B2 (ja) 2017-10-13 2023-07-03 Ldhaの発現を阻害するための方法及び組成物

Country Status (15)

Country Link
US (4) US11286488B2 (cg-RX-API-DMAC7.html)
EP (2) EP3679141B1 (cg-RX-API-DMAC7.html)
JP (2) JP7308213B2 (cg-RX-API-DMAC7.html)
KR (2) KR102609396B1 (cg-RX-API-DMAC7.html)
CN (3) CN111448319B (cg-RX-API-DMAC7.html)
AU (1) AU2018346971B2 (cg-RX-API-DMAC7.html)
CA (1) CA3078933A1 (cg-RX-API-DMAC7.html)
ES (1) ES2955045T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231063T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063026T2 (cg-RX-API-DMAC7.html)
IL (1) IL273875B2 (cg-RX-API-DMAC7.html)
MX (1) MX428940B (cg-RX-API-DMAC7.html)
PL (1) PL3679141T3 (cg-RX-API-DMAC7.html)
RS (1) RS64483B1 (cg-RX-API-DMAC7.html)
WO (1) WO2019075419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351854B2 (en) 2014-10-10 2019-07-16 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
HRP20231063T1 (hr) 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
EP3684377B1 (en) * 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection
EP3710588A4 (en) 2018-01-16 2021-08-18 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US20210115442A1 (en) * 2019-08-23 2021-04-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
US20220389430A1 (en) * 2019-10-02 2022-12-08 Dicema Pharmaceuticals, Inc. Chemical modifications of small interfering rna with minimal fluorine content
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021234543A1 (en) * 2020-05-18 2021-11-25 Chinook Therapeutics Canada, Inc. Substituted pyrazolyl compounds and methods of use thereof
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
TW202233839A (zh) * 2020-11-13 2022-09-01 美商戴瑟納製藥股份有限公司 用於抑制aldh2表現之化學修飾
EP4276104A3 (en) 2021-03-19 2024-05-22 Bachem Holding AG Improved oligonucleotide synthesis suppressing depurination
US20250282813A1 (en) 2021-04-09 2025-09-11 Bachem Holding Ag Pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates
IL307154A (en) * 2021-04-19 2023-11-01 Novo Nordisk As Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
JP2024518564A (ja) * 2021-05-11 2024-05-01 ディセルナ ファーマシューティカルズ インコーポレイテッド 中枢神経系のニューロンを標的とするための脂質コンジュゲーション
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
JP2024528659A (ja) 2021-07-19 2024-07-30 アルナイラム ファーマシューティカルズ, インコーポレイテッド 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
KR20240046843A (ko) * 2021-08-25 2024-04-11 노보 노르디스크 에이/에스 알파-1 항트립신 발현을 억제하기 위한 조성물 및 방법
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
WO2023060141A2 (en) * 2021-10-05 2023-04-13 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting melanocortin 2 receptor and cytochrome p450 11b1 expression
JP7877458B2 (ja) * 2021-12-01 2026-06-22 ディセルナ ファーマシューティカルズ インコーポレイテッド Apoc3発現を調節するための組成物及び方法
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ (シャーメン) バイオファーマ カンパニー,リミテッド 炭水化物-オリゴヌクレオチド複合体、薬物組成物および治療への応用
WO2024061842A1 (en) 2022-09-19 2024-03-28 Bachem Holding Ag Improved oligonucleotide synthesis
WO2024083746A1 (en) 2022-10-17 2024-04-25 Bachem Holding Ag Method and composition for oligonucleotide synthesis
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4695265A1 (en) 2023-10-16 2026-02-18 Bachem Holding AG Method and composition for oligonucleotide synthesis
WO2025196505A2 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
CN118460650B (zh) * 2024-07-10 2025-02-14 凯莱英医药集团(天津)股份有限公司 一种Nedosiran的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10920226B2 (en) 2002-11-14 2021-02-16 Thermo Fisher Scientific Inc. siRNA targeting LDHA
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050014692A1 (en) 2003-01-21 2005-01-20 Newgard Christopher B. Lactate dehydrogenase as a novel target and reagent for diabetes therapy
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
JP2011516065A (ja) * 2008-04-04 2011-05-26 カランド ファーマシューティカルズ, インコーポレイテッド Epas1阻害剤の組成物および使用
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
US20100173973A1 (en) 2008-12-18 2010-07-08 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック, インコーポレイテッド Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
JP2014518626A (ja) 2011-05-18 2014-08-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 被験者が慢性腎疾患を有する、または発症するリスクがあるかどうかを決定するための方法
US9796974B2 (en) 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四galnac之新穎結合物及傳送寡核苷酸之方法
US10351854B2 (en) 2014-10-10 2019-07-16 Dicerna Pharmaceuticals, Inc. Therapeutic inhibition of lactate dehydrogenase and agents therefor
EP3865576A1 (en) * 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US20180051316A1 (en) * 2014-12-18 2018-02-22 The Regents Of The University Of California Detection of nucleic acid polymerase conformational changes using a nanotube
TWI761305B (zh) * 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Hif2α基因表現之組合物及方法
HRP20231063T1 (hr) * 2017-10-13 2023-12-22 Novo Nordisk Health Care Ag Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha

Similar Documents

Publication Publication Date Title
JP2021500025A5 (cg-RX-API-DMAC7.html)
KR102769565B1 (ko) 17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
TWI823866B (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
EP3679141B1 (en) Methods and compositions for inhibiting expression of ldha
TW201726918A (zh) 抑制lpa之基因表現之組合物及方法
US20250319114A1 (en) NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
KR20260007576A (ko) 변형된 가이드 rna
JP2018529732A5 (cg-RX-API-DMAC7.html)
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP7830340B2 (ja) PNPLA3の発現を阻害するためのRNAi薬、その医薬組成物、及び使用方法
CN108064313A (zh) 用于抑制因子xii的基因表达的组合物和方法
JP2022551269A5 (cg-RX-API-DMAC7.html)
JP2023519246A5 (cg-RX-API-DMAC7.html)
JP2025511854A (ja) 非アルコール性脂肪肝疾患の治療
JP2021524277A (ja) Rtel1発現の調節用のオリゴヌクレオチド
JP2020537653A (ja) アシアロ糖タンパク質受容体1の発現を阻害するためのRNAi剤および組成物
JP2022520653A5 (cg-RX-API-DMAC7.html)
WO2025252255A1 (zh) 抑制FXI基因表达的siRNA、其缀合物和药物组合物及用途
CN119144601A (zh) 抑制羧肽酶B2基因表达的siRNA、其缀合物和药物组合物及用途
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法
JP2024547071A (ja) トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
EP4332221A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
WO2026082165A1 (zh) 修饰的双链核糖核酸
CN121022824A (zh) 一种核酸、含有该核酸的组合物与缀合物及用途